Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

About the trial

Sponsor

Molnlycke Health Care AB

Tested

Exufiber (device), Exufiber Ag+ (device)

Dates

Started 2021-03-10; completion 2024-12-31

Results posted

Not yet

This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit. Sixty-eight (68) eligible subjects, with moderate to high exuding partial-thickness burns, will be selected for treatment with either Exufiber Ag+ silver-coated gelling dressing, or Exufiber gelling dressing. The study will last 5 weeks, with a requirement of 5 study visits in total, including dressing changes at each study visit.

From ClinicalTrials.gov, last updated 2024-11-12. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Molnlycke Health Care Ab reported $25,388 in research payments for this study in 2025 (5 payments).

Products named: Mepilex, Exufiber, Exufiber Ag+, Mepilex AG

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.